Author

Shunsuke Izuka

Observed name: S. Izuka

Institution: Astellas Pharma (Japan)

Observed institutions: Astellas Pharma (Japan), Gifu Pharmaceutical University

ORCID: 0000-0002-4060-2589

Observed ORCID: 0000-0002-4060-2589

OpenAlex ID: A5018034953

Gilteritinib Versus Salvage Chemotherapy for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: A Phase 3, Randomized, Multicenter, Open-Label Trial in Asia

2021 · Jianxiang Wang, Bin Jiang, et al. · Blood · 8

A phase III randomized study of gilteritinib versus salvage chemotherapy in FLT3 mutation-positive subjects with relapsed or refractory acute myeloid leukemia

2018 · J. Wang, J. Li, et al. · Annals of Oncology · 2

P554: Gilteritinib Versus Salvage Chemotherapy for Relapsed/refractory Flt3-mutated Acute Myeloid Leukemia: a Phase 3, Randomized, Multicenter, Open-label Trial in Asia

2022 · J. Wang, B. Jiang, et al. · HemaSphere

Characteristics of drugs approved in Japan without conducting confirmatory clinical trials

2021 · Shunsuke Izuka, Naoki Matsumaru, et al. · Journal of Clinical Pharmacy and Therapeutics

Works count: 4

Citation count: 10

H-index: 2

I10-index: